<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="" /><title>6.1 Drugs used in diabetes: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP4032-drugs-used-in-diabetes.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP4032-drugs-used-in-diabetes.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP4032-drugs-used-in-diabetes.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4031-endocrine-system.htm">6 Endocrine system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP4031-endocrine-system.htm" title="Previous: 6 Endocrine system">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP4035-insulins.htm" title="Next: 6.1.1 Insulins">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>6.1 </span>Drugs used in diabetes</h1><?highlighter on?><div id="pC" class="jN"><p>Diabetes mellitus occurs because of a lack of insulin or resistance to its action. It is diagnosed by measuring fasting or random blood-glucose concentration (and occasionally by oral glucose tolerance test). Although there are many subtypes, the two principal classes of diabetes are type 1 diabetes and type 2 diabetes.</p> <p><em>Type 1 diabetes</em>, (formerly referred to as insulin-dependent diabetes mellitus (IDDM)), occurs as a result of a deficiency of insulin following autoimmune destruction of pancreatic beta cells. Patients with type 1 diabetes require administration of insulin.</p> <p><em>Type 2 diabetes</em>, (formerly referred to as non-insulin-dependent diabetes (NIDDM)), is due to reduced secretion of insulin or to peripheral resistance to the action of insulin or to a combination of both. Although patients may be controlled on diet alone, many also require oral antidiabetic drugs or insulin (or both) to maintain satisfactory control. In overweight individuals, type 2 diabetes may be prevented by losing weight and increasing physical activity; use of the anti-obesity drug orlistat (<a title="sub-section: Anti-obesity drugs acting on the gastro-intestinal tract" href="PHP2495-anti-obesity-drugs-acting-on-the-gastro-intestinal-tract.htm">section 4.5.1</a>) may be considered in obese patients.</p> <div><h2>Treatment of diabetes</h2><p>Treatment of all forms of diabetes should be aimed at alleviating symptoms and minimising the risk of long-term complications (see below); tight control of diabetes is essential.</p><p>Diabetes is a strong risk factor for cardiovascular disease (<a title="section: Lipid-regulating drugs" href="PHP1621-lipid-regulating-drugs.htm">section 2.12</a>). Other risk factors for cardiovascular disease such as smoking (<a title="BNF:sub-section: Nicotine Dependence" href="PHP3188-nicotine-dependence.htm">section 4.10.2</a>), hypertension (<a title="section: Drugs affecting the renin-angiotensin system and some other antihypertensive drugs" href="PHP1034-hypertension-and-heart-failure.htm">section 2.5</a>), obesity (<a title="section: Drugs used in the treatment of obesity" href="PHP2494-drugs-used-in-the-treatment-of-obesity.htm">section 4.5</a>), and hyperlipidaemia (<a title="section: Lipid-regulating drugs" href="PHP1621-lipid-regulating-drugs.htm">section 2.12</a>) should be addressed. Cardiovascular risk in patients with diabetes can be further reduced by the use of an ACE inhibitor (<a title=" Angiotensin-converting enzyme inhibitors" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">section 2.5.5.1</a>), low-dose aspirin (<a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>) and a lipid-regulating drug (<a title="section: Lipid-regulating drugs" href="PHP1621-lipid-regulating-drugs.htm">section 2.12</a>).</p></div> <div><h2>Prevention of diabetic complications</h2><p>Optimal glycaemic control in both type 1 diabetes and type 2 diabetes reduces, in the long term, the risk of microvascular complications including retinopathy, development of proteinuria and to some extent neuropathy. However, a temporary deterioration in established diabetic retinopathy may occur when normalising blood-glucose concentration. For reference to the use of an ACE inhibitor or an angiotensin-II receptor antagonist in the management of diabetic nephropathy, see <a title=" Treatment of diabetic nephropathy and neuropathy" href="PHP4232-treatment-of-diabetic-nephropathy-and-neuropathy.htm">section 6.1.5</a>.</p><p>A measure of the total glycosylated (or glycated) haemoglobin (HbA<sub>1</sub>) or a specific fraction (HbA<sub>1c</sub>) provides a good indication of glycaemic control over the previous 2–3 months. Overall it is ideal to aim for an HbA<sub>1c</sub> (glycosylated haemoglobin) concentration of 48–59 mmol/mol or less (reference range 20–42 mmol/mol) but this cannot always be achieved and for those using insulin there is a significantly increased risk of disabling hypoglycaemia; in those at risk of arterial disease, the aim should be to maintain the HbA<sub>1c</sub> concentration at 48 mmol/mol or less. HbA<sub>1c</sub> should be measured every 3–6 months.</p><div class="cI"><h3 class="cT">Measurement of HbA<sub>1c</sub></h3><p>HbA<sub>1c</sub> values were previously aligned to the assay used in the Diabetes Control and Complications Trial (DCCT) and expressed as a percentage. A new standard, specific for HbA<sub>1c</sub>, has been created by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), which expresses HbA<sub>1c</sub> values in <em>mmol of glycosylated haemoglobin per mol of haemoglobin</em>. From <strong>1 June 2011</strong> UK laboratories will only express results in IFCC-standardised units (mmol/mol).</p> <div class="table" id="PHP4033"> <div class="cAA">Equivalent values</div> <table class="table" summary="Equivalent values" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; border-left: 1pt solid ; border-right: 1pt solid ; "><colgroup><col /><col /></colgroup><thead><tr style="border-bottom: 1pt solid ; "><th style="border-bottom: 1pt solid ; ">IFCC-HbA<sub>1c</sub> (mmol/mol)</th><th style="border-bottom: 1pt solid ; ">DCCT-HbA<sub>1c</sub> (%) </th></tr></thead><tbody><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">42</td><td style="border-bottom: 1pt solid ; ">6.0</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">48</td><td style="border-bottom: 1pt solid ; ">6.5</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">53</td><td style="border-bottom: 1pt solid ; ">7.0</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">59</td><td style="border-bottom: 1pt solid ; ">7.5</td></tr><tr style="border-bottom: 1pt solid ; "><td style="border-bottom: 1pt solid ; ">64</td><td style="border-bottom: 1pt solid ; ">8.0</td></tr><tr><td style="">75</td><td style="">9.0</td></tr></tbody></table></div> </div><p>Laboratory measurement of serum-fructosamine concentration is technically simpler and cheaper than the measurement of HbA<sub>1c</sub> and can be used to assess control over short periods of time, particularly when HbA<sub>1c</sub> monitoring is invalid (e.g. disturbed erythrocyte turnover or abnormal haemoglobin type).</p><p>Tight control of blood pressure in hypertensive patients with type 2 diabetes reduces mortality and protects visual acuity (by reducing considerably the risks of maculopathy and retinal photocoagulation) (see also <a title=" Drugs affecting the renin-angiotensin system and some other antihypertensive drugs" href="PHP1034-hypertension-and-heart-failure.htm">section 2.5</a>).</p></div> <div id="PHP4034"><h2>Driving</h2><p>Drivers with diabetes are required to notify the Driver and Vehicle Licensing Agency (DVLA) of their condition if they are treated with insulin or if they are treated with oral antidiabetic drugs and also have complications. Detailed guidance on eligibility to drive is available from the DVLA (<a href="http://www.dvla.gov.uk/medical.aspx">www.dvla.gov.uk/medical.aspx</a>). Driving is not permitted when hypoglycaemic awareness is impaired or frequent hypoglycaemic episodes occur.</p><p>Drivers need to be particularly careful to avoid hypoglycaemia (see also above) and should be warned of the problems. Drivers treated with insulin should normally check their blood-glucose concentration before driving and, on long journeys, at 2-hour intervals; these precautions may also be necessary for drivers taking oral antidiabetic drugs who are at particular risk of hypoglycaemia. Drivers treated with insulin should ensure that a supply of sugar is always available in the vehicle and they should avoid driving if their meal is delayed. If hypoglycaemia occurs, or warning signs develop, the driver should:</p><ul><li><p>stop the vehicle in a safe place;</p> </li><li><p>switch off the ignition;</p> </li><li><p>eat or drink a suitable source of sugar;</p> </li><li><p>wait until recovery is complete before continuing journey; recovery may take 15 minutes or longer and should preferably be confirmed by checking blood-glucose concentration.</p> </li></ul></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP4035-insulins"><a href="PHP4035-insulins.htm" title="6.1.1 Insulins">6.1.1 Insulins</a></li><li id="_PHP4127-antidiabetic-drugs"><a href="PHP4127-antidiabetic-drugs.htm" title="6.1.2 Antidiabetic drugs">6.1.2 Antidiabetic drugs</a></li><li><a href="PHP4222-diabetic-ketoacidosis.htm" title="6.1.3 Diabetic ketoacidosis">6.1.3 Diabetic ketoacidosis</a></li><li id="_PHP4223-treatment-of-hypoglycaemia"><a href="PHP4223-treatment-of-hypoglycaemia.htm" title="6.1.4 Treatment of hypoglycaemia">6.1.4 Treatment of hypoglycaemia</a></li><li id="_PHP4232-treatment-of-diabetic-nephropathy-and-neuropathy"><a href="PHP4232-treatment-of-diabetic-nephropathy-and-neuropathy.htm" title="6.1.5 Treatment of diabetic nephropathy and neuropathy">6.1.5 Treatment of diabetic nephropathy and neuropathy</a></li><li id="_PHP4235-diagnostic-and-monitoring-devices-for-diabetes-mellitus"><a href="PHP4235-diagnostic-and-monitoring-devices-for-diabetes-mellitus.htm" title="6.1.6 Diagnostic and monitoring devices for diabetes mellitus">6.1.6 Diagnostic and monitoring devices for diabetes mellitus</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP4031-endocrine-system.htm">Previous: 6 Endocrine system</a> | <a class="top" href="PHP4032-drugs-used-in-diabetes.htm#">Top</a> | <a accesskey="]" href="PHP4035-insulins.htm">Next: 6.1.1 Insulins</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>